What is Biocorrx Inc's earnings per share (EPS)?

Biocorrx Inc (BICX) reported diluted earnings per share of -$0.19 for fiscal year 2025. This represents a 61.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Biocorrx Inc Financials

BICX

FY2025 annual

Revenue $797K +10301.1% YoY

Net Income -$3.4M YoY not available

EPS (Diluted) -$0.19 +61.2% YoY

Free Cash Flow Not reported for FY2025

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 14, 2026 Currency USD FYE December

Biocorrx Inc (BICX) reported $797K in revenue for fiscal year 2025, up 10301.1% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BICX FY2025 2026-08-29

BioCorRx remains a development-stage operation where financing, not operating cash generation, supports a cost base still larger than revenue.

The FY2025 revenue rebound to $797K did not translate into operating efficiency: the operating profit margin was -606.0%, indicating that scale remained far below the level needed to absorb operating costs. Operating cash flow was -$2.3M while financing provided $2.3M, linking the reported funding activity directly to the cash shortfall rather than to internally generated funds.

Research and development consumed $1.8M against $797K of revenue in FY2025, confirming that the business is still funding development at a scale larger than its commercial inflow. Combined with selling, general and administrative expense of $3.8M, the cost structure explains why revenue recovery has not yet produced operating profit.

The balance sheet is structurally impaired: $13.7M of liabilities stood against $2.1M of assets in FY2025, leaving negative equity. A current ratio of 0.1x and reported liquidity equal to 0.7 months of annual operating outflow point to severe short-term coverage pressure alongside the longer-term deficit.

Financial Health Signals

Financial health score not available

Biocorrx Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-67.46

Biocorrx Inc scores -67.46, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($6.2M) relative to total liabilities ($13.7M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/6

Biocorrx Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 3 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Biocorrx Inc reported a net loss of $3.4M while operations used $2.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Biocorrx Inc reported an operating loss of $4.8M against $224K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$797K

YoY+10301.1%

5Y CAGR+45.4%

10Y CAGR-1.5%

Biocorrx Inc generated $797K in revenue in fiscal year 2025. This represents an increase of 10301.1% from the prior year.

EBITDA

-$4.8M

Biocorrx Inc's EBITDA was -$4.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Net Income

-$3.4M

Biocorrx Inc reported -$3.4M in net income in fiscal year 2025.

EPS (Diluted)

-$0.19

YoY+61.2%

Biocorrx Inc earned -$0.19 per diluted share (EPS) in fiscal year 2025. This represents an increase of 61.2% from the prior year.

Cash & Balance Sheet

Cash & Debt

$139K

YoY+58.3%

5Y CAGR-25.1%

10Y CAGR-4.5%

Biocorrx Inc held $139K in cash as of fiscal year 2025; long-term debt is not reported for that period.

Shares Outstanding

26M

YoY+64.0%

5Y CAGR+32.0%

Biocorrx Inc had 26M shares outstanding in fiscal year 2025. This represents an increase of 64.0% from the prior year.

Free Cash Flow

Not reported for fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$1.8M

YoY+19.3%

5Y CAGR-16.2%

Biocorrx Inc invested $1.8M in research and development in fiscal year 2025. This represents an increase of 19.3% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

Capital Expenditures

Not reported for fiscal year 2025.

BICX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BICX quarterly income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	N/A	$797K+10301.1%	$8K-91.4%	$89K-58.3%	$214K+343.0%	$48K-60.6%	$123K-49.0%	$240K-36.2%	$377K-42.7%	$657K-6.3%	$702K-24.1%	$925K-21.0%	$1.2M+63.8%	$715K-17.6%	$868K+12.5%	$772K
Cost of Revenue	N/A	N/A	$2K-95.4%	$36K+89.9%	$19K+222.2%	$6K-93.9%	$96K+17.5%	$82K-52.2%	$171K-47.2%	$324K+84.5%	$175K+15.4%	$152K-31.2%	$221K+37.9%	$160K-60.2%	$402K+0.5%	$400K
Gross Profit	N/A	N/A	$6K-88.7%	$53K-72.7%	$195K+359.8%	$42K+58.9%	$27K-83.2%	$159K-22.9%	$206K-38.4%	$334K-36.6%	$526K-31.9%	$773K-18.7%	$950K+71.2%	$555K+19.1%	$466K+25.4%	$371K
R&D Expenses	N/A	$1.8M+19.3%	$1.5M+66.4%	$891K-38.9%	$1.5M-9.1%	$1.6M-62.4%	$4.3M+279.9%	$1.1M+641.3%	$152K-66.3%	$451K	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	$3.8M	N/A	N/A	$3.4M-8.9%	$3.7M+18.1%	$3.2M-30.6%	$4.6M	N/A	$2.7M+7.6%	$2.5M+19.7%	$2.1M-45.0%	$3.9M+32.5%	$2.9M+168.7%	$1.1M+52.2%	$714K
Operating Income	N/A	-$4.8M	N/A	N/A	N/A	N/A	-$7.5M-34.7%	-$5.6M	N/A	-$2.9M-32.5%	-$2.2M+57.4%	-$5.1M-67.7%	-$3.1M	N/A	N/A	N/A
Interest Expense	N/A	$224K-71.2%	$777K+300.3%	$194K+28.5%	$151K+677.2%	$19K-96.2%	$511K-68.5%	$1.6M+182.8%	-$2.0M	N/A	$1.0M+177.9%	$377K+6.9%	$353K+13.7%	$310K	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0	$0	$0	N/A	N/A	N/A	N/A	N/A	$2K0.0%	$2K	N/A
Net Income	N/A	-$3.4M	N/A	N/A	N/A	N/A	-$3.5M+42.0%	-$6.0M	N/A	N/A	N/A	-$4.7M-49.2%	-$3.1M+18.5%	-$3.8M-333.3%	-$886K-116.6%	-$409K
EPS (Diluted)	—	-$0.19+61.2%	-$0.49	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$88K-59.0%	$215K	N/A	$635K+256.4%	$178K+32.1%	$135K	N/A	$0
Cost of Revenue	$145K+475.6%	$25K	N/A	N/A	$0	$0	N/A	$0
Gross Profit	-$57K-130.1%	$189K	N/A	N/A	$178K+32.1%	$135K	N/A	$0
R&D Expenses	$712K+102.2%	$352K	N/A	$1.0M+238.4%	$297K+83.3%	$162K	N/A	$460K
SG&A Expenses	$686K-11.5%	$775K	N/A	$1.1M-6.4%	$1.2M+38.1%	$886K	N/A	$1.2M
Operating Income	-$1.5M-53.3%	-$956K	N/A	-$1.9M-37.6%	-$1.4M-50.7%	-$938K	N/A	-$1.7M
Interest Expense	$30K-3.2%	$31K	N/A	$30K-19.1%	$37K-58.1%	$87K	N/A	$149K
Income Tax	$0	$0	N/A	N/A	$0	$0	N/A	$0
Net Income	-$965K-16.1%	-$831K	N/A	-$1.9M-55.5%	-$1.2M-46.6%	-$841K	N/A	-$1.5M
EPS (Diluted)	-$0.030.0%	-$0.03-160.0%	$0.05	-$0.11-57.1%	-$0.07-16.7%	-$0.06+25.0%	-$0.08+42.9%	-$0.14

BICX Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BICX quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$2.1M+456.4%	$386K-0.8%	$389K-49.3%	$767K-6.5%	$820K-55.1%	$1.8M-53.5%	$3.9M+526.1%	$628K+85.4%	$339K-28.0%	$470K-66.5%	$1.4M-65.6%	$4.1M-7.7%	$4.4M-12.9%	$5.1M+850.8%	$535K
Current Assets	$814K+590.3%	$118K-36.9%	$187K-41.0%	$317K+38.8%	$228K-76.6%	$975K-68.0%	$3.0M+854.3%	$319K+485.7%	$55K-46.0%	$101K-67.7%	$312K+46.3%	$213K-55.1%	$475K-57.0%	$1.1M	N/A
Cash & Equivalents	$139K+58.3%	$88K+35.0%	$65K-4.9%	$69K-20.1%	$86K-85.5%	$592K-77.6%	$2.6M+845.7%	$280K+2366.7%	$11K-87.7%	$92K-58.0%	$220K+314.3%	$53K-51.1%	$109K+1708.8%	$6K+262.2%	$2K
Inventory	$143K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$253K	$0-100.0%	$740-97.9%	$35K+2258.5%	$2K+200.0%	$500-33.3%	$750-90.6%	$8K-73.3%	$30K	N/A	$3K-96.5%	$79K-73.8%	$299K+132.3%	-$926K-75.1%	-$529K
Goodwill	$563K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$13.7M+9.3%	$12.5M+22.5%	$10.2M+13.9%	$9.0M+15.3%	$7.8M+28.9%	$6.0M+20.9%	$5.0M-21.2%	$6.3M+49.7%	$4.2M-50.8%	$8.6M+83.5%	$4.7M+24.1%	$3.8M-10.1%	$4.2M+87.1%	$2.2M+176.0%	-$3.0M
Current Liabilities	$8.3M+1.2%	$8.2M+27.6%	$6.4M+19.9%	$5.4M+22.3%	$4.4M+43.7%	$3.1M+19.7%	$2.6M-58.4%	$6.1M+273.9%	$1.6M-33.2%	$2.5M-34.7%	$3.8M+93.8%	$1.9M+42.3%	$1.4M-31.3%	$2.0M+93.5%	$1.0M
Long-Term Debt	N/A	N/A	N/A	$0-100.0%	$100K	N/A	N/A	N/A	N/A	N/A	$1.9M+141.1%	$770K-31.6%	$1.1M	N/A	N/A
Total Equity	-$11.2M+7.4%	-$12.1M-23.4%	-$9.8M-21.6%	-$8.1M-16.0%	-$7.0M-65.3%	-$4.2M-297.6%	-$1.1M+81.4%	-$5.7M-46.6%	-$3.9M+52.1%	-$8.1M-147.7%	-$3.3M-1171.8%	$306K+37.5%	$223K-92.1%	$2.8M-18.7%	$3.5M
Retained Earnings	-$86.6M-4.1%	-$83.2M-6.5%	-$78.1M-5.1%	-$74.3M-6.2%	-$70.0M-8.2%	-$64.7M-5.7%	-$61.2M-10.9%	-$55.2M-13.0%	-$48.8M-155.2%	-$19.1M-44.6%	-$13.2M-54.5%	-$8.6M-57.5%	-$5.4M-240.1%	-$1.6M-124.3%	-$713K

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$1.9M-18.0%	$2.3M+8.3%	$2.1M-71.5%	$7.5M+12.8%	$6.7M-1.8%	$6.8M+1662.2%	$386K-40.0%	$644K
Current Assets	$623K-38.9%	$1.0M+25.3%	$814K-44.3%	$1.5M+177.2%	$527K-6.8%	$566K+379.5%	$118K-66.6%	$353K
Cash & Equivalents	$21K-90.0%	$212K+52.1%	$139K-51.6%	$288K+157.2%	$112K+363.4%	$24K-72.6%	$88K+97714.4%	$90
Inventory	$44K-69.6%	$143K0.0%	$143K-7.7%	$155K+16.3%	$134K0.0%	$134K	$0	N/A
Accounts Receivable	$68K-79.5%	$330K+30.3%	$253K+30.4%	$194K+279.5%	$51K-54.2%	$112K	$0	$0
Goodwill	$563K0.0%	$563K0.0%	$563K-80.2%	$2.8M0.0%	$2.8M0.0%	$2.8M	$0	N/A
Total Liabilities	$14.4M+3.1%	$13.9M+2.0%	$13.7M-32.6%	$20.3M+3.1%	$19.7M+5.9%	$18.6M+48.7%	$12.5M+0.3%	$12.5M
Current Liabilities	$8.9M+3.8%	$8.5M+2.7%	$8.3M-44.8%	$15.0M+3.3%	$14.6M+8.3%	$13.4M+63.8%	$8.2M-0.2%	$8.2M
Total Equity	-$12.2M-6.8%	-$11.5M-2.0%	-$11.2M+16.8%	-$13.5M-6.8%	-$12.6M-9.2%	-$11.6M+4.7%	-$12.1M-2.4%	-$11.8M
Retained Earnings	-$88.6M-1.2%	-$87.5M-1.0%	-$86.6M+0.6%	-$87.2M-2.2%	-$85.3M-1.5%	-$84.1M-1.0%	-$83.2M-1.4%	-$82.0M

Not reported in any period shown, so not listed: Long-Term Debt.

BICX Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

BICX quarterly cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$2.4M	-$2.3M-109.6%	-$1.1M+40.8%	-$1.9M+9.2%	-$2.0M+42.3%	-$3.5M-64.4%	-$2.2M+26.7%	-$2.9M-60.9%	-$1.8M+28.1%	-$2.5M-27.1%	-$2.0M-4277.7%	$48K-71.5%	$168K+62.1%	$103K+111.2%	-$928K-622.6%	-$128K
Capital Expenditures	N/A	N/A	N/A	N/A	$0-100.0%	$2K	$0-100.0%	-$123K+1125.9%	$10K+236.7%	$3K-99.0%	$306K	N/A	$487-92.7%	$7K+712.8%	$820	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	-$2.0M+42.3%	-$3.5M-64.5%	-$2.2M+29.7%	-$3.1M-66.7%	-$1.8M+27.8%	-$2.5M-10.3%	-$2.3M	N/A	$167K+72.7%	$97K+110.4%	-$929K	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	$0+100.0%	-$50K-441.9%	-$9K+92.4%	-$122K-117.7%	-$56K-1783.7%	-$3K+99.1%	-$328K	N/A	-$33K+5.3%	-$35K+54.2%	-$76K-1395.8%	-$5K
Financing Cash Flow	$2.3M	$2.3M+110.0%	$1.1M-39.5%	$1.8M-8.6%	$2.0M-34.3%	$3.1M+2771.8%	$107K-98.0%	$5.4M+152.3%	$2.1M-10.9%	$2.4M+7.2%	$2.3M+1789.5%	$119K+162.6%	-$190K-662.3%	$34K-96.6%	$1.0M+687.5%	$128K

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$440K-1.7%	-$433K+48.9%	-$848K-33.6%	-$634K-401.5%	-$126K+81.7%	-$690K-179.0%	-$247K+30.9%	-$358K
Financing Cash Flow	$250K-50.6%	$506K-27.7%	$699K-13.7%	$810K+278.2%	$214K-65.8%	$626K+86.7%	$335K-4.1%	$349K

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

BICX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

BICX quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	N/A	78.3%+18.6pp	59.6%-31.5pp	91.1%+3.3pp	87.8%+66.1pp	21.8%-44.3pp	66.0%+11.4pp	54.6%+3.8pp	50.8%-24.2pp	75.0%-8.6pp	83.6%+2.4pp	81.1%+3.5pp	77.6%+24.0pp	53.6%+5.5pp	48.1%
Operating Margin	-606.0%	N/A	N/A	N/A	N/A	-6109.9%	-2314.7%	N/A	-439.8%	-310.9%	-553.5%	-260.7%	N/A	N/A	N/A
Net Margin	-431.5%	N/A	N/A	N/A	N/A	-2859.6%	-2517.4%	N/A	N/A	N/A	-504.6%	-267.1%	-536.9%	-102.0%	-53.0%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-1021.1%+701.8pp	-1722.9%-1691.7pp	-31.2%-19.5pp	-11.7%
Return on Assets	-160.2%	N/A	N/A	N/A	N/A	-191.9%-38.2pp	-153.8%	N/A	N/A	N/A	-332.0%-255.4pp	-76.6%+10.1pp	-86.7%-69.3pp	-17.4%+59.1pp	-76.5%
Current Ratio	0.10+0.1x	0.010.0x	0.030.0x	0.060.0x	0.05-0.3x	0.32-0.9x	1.19+1.1x	0.050.0x	0.030.0x	0.040.0x	0.080.0x	0.11-0.2x	0.35-0.2x	0.56	N/A
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	2.51-2.5x	5.05+4.3x	0.79	N/A
FCF Margin	N/A	N/A	N/A	-954.8%	-7332.8%	-1754.9%	-1273.5%	-487.4%	-387.0%	-328.5%	N/A	14.3%+0.7pp	13.5%	-107.0%	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	-64.8%-153.1pp	88.3%	N/A	N/A	100.0%0.0pp	100.0%	N/A	N/A
Operating Margin	-1666.0%	-445.6%	N/A	-306.3%	-793.3%	-695.3%	N/A	N/A
Net Margin	-1096.7%	-387.4%	N/A	-301.9%	-692.0%	-623.7%	N/A	N/A
Return on Assets	-50.6%-14.8pp	-35.8%	N/A	-25.5%-7.0pp	-18.5%-6.1pp	-12.4%	N/A	-231.1%
Current Ratio	0.070.0x	0.120.0x	0.100.0x	0.10+0.1x	0.040.0x	0.040.0x	0.010.0x	0.04

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Note: Shareholder equity is negative (-$11.2M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.10), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Veltex VLXC

$4.9M

Xcelerate Inc XCRT

$4.8M

Aesthetic Medical International Holdings Group Ltd PAIYY

$711K

Numinus Wellness Inc. NUMIF

$10.6M

Selectis Health Inc GBCS

$16.7M

Where Biocorrx Inc Ranks

Frequently Asked Questions

What is Biocorrx Inc's annual revenue?

Biocorrx Inc (BICX) reported $797K in total revenue for fiscal year 2025. This represents a 10301.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Biocorrx Inc's revenue growing?

Biocorrx Inc (BICX) revenue grew by 10301.1% year-over-year, from $8K to $797K in fiscal year 2025.

Is Biocorrx Inc profitable?

No, Biocorrx Inc (BICX) reported a net income of -$3.4M in fiscal year 2025.

What is Biocorrx Inc's EBITDA?

Biocorrx Inc (BICX) had EBITDA of -$4.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Biocorrx Inc's operating cash flow?

Biocorrx Inc (BICX) recorded an outflow of $2.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Biocorrx Inc's total assets?

Biocorrx Inc (BICX) had $2.1M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Biocorrx Inc spend on research and development?

Biocorrx Inc (BICX) invested $1.8M in research and development during fiscal year 2025.

How many shares does Biocorrx Inc have outstanding?

Biocorrx Inc (BICX) had 26M shares outstanding as of fiscal year 2025.

What is Biocorrx Inc's current ratio?

Biocorrx Inc (BICX) had a current ratio of 0.10 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Biocorrx Inc's return on assets (ROA)?

Biocorrx Inc (BICX) had a return on assets of -160.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does Biocorrx Inc's liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Biocorrx Inc (BICX) held $139K in cash, cash equivalents and investments, and reported an operating cash outflow of $2.3M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is Biocorrx Inc's debt-to-equity ratio negative or not reported?

Biocorrx Inc (BICX) has negative shareholder equity of -$11.2M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Biocorrx Inc's Altman Z-Score?

Biocorrx Inc (BICX) has an Altman Z-Score of -67.46, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Biocorrx Inc's Piotroski F-Score?

Biocorrx Inc (BICX) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Biocorrx Inc's earnings high quality?

Biocorrx Inc (BICX) reported a net loss of $3.4M while operations used $2.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Biocorrx Inc cover its interest payments?

Biocorrx Inc (BICX) reported an operating loss of $4.8M against $224K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.